More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...

These drugs, discovered decades ago, continue to save lives today, but more recent research has led to the development of ...

Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...